Organization · Venture Capital
Scion Life Sciences
Scion Life Sciences is a New York City-based venture capital firm focused on founding and building biotechnology companies that develop transformative medicines for serious diseases. The firm emphasizes a data-driven approach to company formation.
Overview
What Scion Life Sciences does
What Scion Life Sciences is
Scion Life Sciences is a New York City-based venture capital firm focused on founding and building biotechnology companies that develop transformative medicines for serious diseases. The firm emphasizes a data-driven approach to company formation.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2024
- Approximate age
- About 2 years
- Structured capabilities
- Funder
- Last reviewed
- April 26, 2026
Official channels
Find Scion Life Sciences elsewhere
Open the official website or a supported primary organization account.
Capability profile
Scion Life Sciences as a funder
Investment thesis
Scion Life Sciences focuses on creating and building biotechnology companies that develop clinically transformational or curative medicines, prioritizing meaningful innovations over exits.
Focus narrative
Scion Life Sciences invests in biotechnology companies that address clinically important problems. Their investment strategy is centered on creating important new medicines rather than focusing on exits. They employ a disciplined approach to capital deployment, guided by three investment pillars: mature modality, well-understood biology and pathophysiology, and standalone viability. The firm is open to sourcing innovation from both academic and industry partners, as well as developing ideas internally.
Value beyond capital
Scion Life Sciences provides significant value to its portfolio companies through its in-house R&D capabilities, which include biologics, protein engineering, candidate testing, and protein expression and characterization. The firm supports companies from early incubation through late-stage clinical maturity or IPO, ensuring a comprehensive approach to building successful biotech ventures.
Terms and economics
- Typical check
- $1,000–$60,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Growth Equity · Ipo
- Regions
- North AmericaUnited States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 10
Portfolio context
Scion Life Sciences has been involved in founding or building ten companies over the past decade, which have collectively advanced over 15 clinical-stage therapeutics and generated more than $14 billion in public equity value and announced M&A proceeds. Currently, they are incubating three undisclosed companies led by newly appointed venture partners.
Common questions
What to know about Scion Life Sciences
Upseed classifies Scion Life Sciences under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.